Watfa Al-Mamari is a developmental pediatrician who established the first developmental pediatric clinics in Oman in 2011. She has worked closely with academic institutions to ensure that developmental pediatrics is included in the curriculum for both undergraduate and postgraduate students. She has a special interest in autism and led the team to establish a national program in Oman to screen children for autism at 18 months of age.
Al-Mamari graduated from Sultan Qaboos University in Muscat, Oman, and later did her residency and fellowship at McGill University in Montreal, Canada.
Watfa Al-Mamari
Developmental pediatrician
Sultan Qaboos University
From this contributor
How one doctor made Oman a leader on autism in the Middle East
Developmental pediatrician Watfa Al-Mamari is building an autism program in Oman from the ground up.
How one doctor made Oman a leader on autism in the Middle East
Explore more from The Transmitter
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.